Systemic interventions available for MPS include Haematopoietic Stem Cell 55

Transplantation (HSCT) and Enzyme Replacement Therapy (ERT). 56
Importantly, these can result in improvement of systemic manifestations and 57 lifespan.
[5] Biochemical parameters have previously been validated as 58 markers of efficacy of HSCT and ERT, [6] [7] [8] and a correlation between 59 treatment efficacy and systemic and ocular outcomes has been shown in 60 MPSI Hurler treated with HSCT. [9] No such relationship has been shown 61 between ERT and ocular phenotype. This may be related to the fact that ERT 62 
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The median VA was 0.4 logMAR in the MPSI group, 0.16 logMAR in MPSIV 119 and 0.2 logMAR in MPSVI (Supplementary Figure 1a) 
123
Anterior segment 124
Clinically all 28 patients showed some degree of corneal clouding. A notable 125 proportion of patients (13/28) showed mild (grade 1) corneal clouding. The 126 MPSI group had a higher proportion of patients with moderate to severe 127 (grades 2 and 3) corneal clouding (13/21 of MPSI patients compared to 1/4 of 128
MPSIV and 1/3 of MPSVI). 129
Corneal clouding was assessed objectively using the Pentacam system 130 (densitometry measure) and an iris camera (COM score). No association 131 between VA and COM score (Figure 1a ) or between VA and Pentacam 132 densitometry ( Figure 1b) scores of between 38.1 and 54.9 (Figure 1d) . Notably, the Pentacam was 143 unable to take pictures for two study participants with significant corneal 144 clouding (subjects 4 and 28; Supplementary Table2). 145
146
Posterior segment 147
Seven MPSI patients had retinopathy confirmed on full field 148 electroretinograms, all of which revealed predominant rod system dysfunction 149 (Table 2) . Retinal pigment epithelial changes were seen in 4 of these patients 150 on fundoscopy. In 2 patients the fundal view was limited due to significant 151 corneal clouding. One patient with no evidence of retinopathy on fundoscopy 152 had electroretinographic evidence of rod system dysfunction (subject 12: 153
MPSI, 7years old). 154
Two study participants were noted to have small, crowded optic nerve heads 155 clinically, in keeping with Optos fundus imaging findings. Small crowded discs 156
were noted on Optos imaging in another patient (subject 9; Figure 3d The median DS/CS ratio in MPSI patients with retinopathy was 0.49 (n=7) 207 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Over the past few decades the development of treatments for MPS has 224 greatly improved systemic outcomes and quality of life in patients with MPS. 225
Given this, it is important that we try to better understand the MPS-associated 226 ocular phenotype. In this study we used objective measures to assess the 227 ocular phenotype in patients with MPS. Correlations between these 228 measures, the MPS type, treatment, biomarkers and genotype were sought. 229
A notable finding of this study is the lack of significant correlation between the 230 level of MPS-associated corneal clouding and visual acuity. VA 231 Pentacam was unable to take corneal opacification measures when there was 246 severe corneal clouding, which may limit its use in the more severe MPS 247 ocular phenotypes. The iris camera COM score was found to be higher in 248 those with moderate corneal clouding compared to those with mild corneal 249 clouding as assigned by subjective clinical grading. However, there is a 250 significant overlap in the observed scores for these subjective grades. One 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
MPSI patient eyes. This feature has been previously described in individuals 267
with MPS, [18, 19] and is thought to reflect thickening of the External Limiting 268
Membrane (ELM). 269
Despite variable image quality obtained with the Optos imaging system, 270 fundoscopic findings that were not detected by slit-lamp examination were 271 highlighted. In one MPSI patient, evidence of peripheral retinopathy was 272 noted on Optos, which had not been suspected clinically. In a different patient, 273 crowded optic disc clearly seen on Optos imaging had not been appreciated 274 clinically. Wide-field imaging can therefore be useful in detecting and 275 monitoring optic nerve and retinal changes, particularly when the changes are 276 peripheral. Interestingly, one patient with electroretinographic abnormality had 277 normal Optos imaging, suggesting that electrodiagnostic testing maybe better 278 at detecting early retinopathy compared to imaging. 279
Previous studies have demonstrated an association between efficacy of 280 treatment (demonstrated by biomarkers) and corneal clouding in patients with 281 MPSI. [9, 20, 21] In this study, median DC/CS or median KS/CS ratios were 282 found to generally increase with increasing grades of corneal clouding in 25 283 patients. Furthermore, median post-HSCT enzyme levels were lower in those 284 with moderate corneal clouding compared to those with mild corneal clouding, 285 also suggesting an association between the ocular phenotype and 286
biomarkers. 287
In this study we have attempted to quantify the degree of corneal clouding 288 and assess the clinical utility of fundus imaging in children and adults with 289
MPS. Limitations of this study include small numbers in MPSIV and MPSVI 290
groups, and the absence of all imaging modalities being obtained for all 291 participants. However, the rare nature of this condition and patient factors 292 such as easy fatigability, skeletal deformity and intellectual difficulties makes 293 addressing these limitations challenging. 294
We found significant variability in the ocular phenotype associated with MPS 295 but the causes of this variability remain poorly understood. It is unclear to 296 what extent the varying effect of genotype or enzyme levels contributes to this 297 variability and future prospective studies of large, well characterised MPS 298 cohorts are expected to provide important insights. 299
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